LRP11通过MAPK13介导的TCF1酸化促进干状T细胞,增强抗PD1免疫疗法
Lingjuan Sun1, Zhibo Ma1, Xiangli Zhao1
1Institute of Organ Transplantation,Tongji Hospital, Tongji Medical College; Key Laboratory of Organ Transplantation; Ministry of Education, NHC Key Laboratory of Organ Transplantation; Key Laboratory of Organ Transplantation, Chinese Academy of Medical Science, Huazhong University of Science and Technology, Wuhan, China.
低密度脂蛋白 (LDL) 通过LRP11和MAPK13激活TCF1+CD8+T细胞,增强抗瘤免疫力. 这一途径促进了类似干细胞的T细胞,这对于有效的免疫疗法反应至关重要.
科学领域:
- 免疫学 免疫学 免疫学
- 癌症生物学 癌症生物学
- 分子医学是分子医学.
背景情况:
- 瘤透的T细胞可能会耗尽,限制身体对抗癌症的能力.
- TCF1+ CD8+ T细胞具有类似干细胞的特性,对免疫治疗反应至关重要.
- 免疫疗法中TCF1的调节及其与身体质量指数等因素的联系仍然不清楚.
研究的目的:
- 研究低密度脂蛋白 (LDL) 影响TCF1+CD8+T细胞的机制.
- 阐明LRP11和MAPK13在调节TCF1和T细胞功能的作用.
- 探索准LRP11-MAPK13-TCF1轴以增强抗瘤免疫力的潜力.
主要方法:
- 利用体外测试来评估淋巴细胞增殖和LDL,LRP11和MAPK13抑制剂的影响.
- 采用携带瘤的小鼠模型 (B16或MC38细胞) 来评估调节剂对瘤生长的体内影响.
- 应用流式细胞计量,西式涂抹,shRNA技术和RNA测序来分析T细胞种群,激活状态和分子相互作用.
主要成果:
- 发现低密度脂蛋白 (LDL) 在小鼠模型中诱导瘤透的TCF1+PD1+CD8+T细胞.
- LRP11被确定为激活TCF1的LDL受体,增强T细胞介导的抗瘤免疫力.
- 证明LRP11激活诱导MAPK13激活,然后酸化TCF1,增加类似干细胞的T细胞.
结论:
- LRP11-MAPK13-TCF1信号通路是瘤微环境中T细胞功能的关键调节者.
- 这种途径的激活通过促进瘤透的类似T细胞的产生来增强抗瘤免疫力.
- 针对LRP11-MAPK13-TCF1轴是改善免疫治疗结果的潜在策略.
更多相关视频
09:15Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
10:44A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants
Published on: August 9, 2019
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
MAPK Signaling Cascades
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
